Vaxem Hib®

	Next higher product group	vaccine, influenza_o
	Status	2017-05-09 production end
	Organisation	GSK (Group)
	Organisation 2	Novartis AG (NYSE: NVS)
	Group	Novartis (Group)

Record changed: 2023-07-10

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

More documents for vaccine, influenza

[1] CureVac N.V.. (7/3/24). "Press Release: GSK and CureVac to Restructure Collaboration into New Licensing Agreement". London, Tübingen & Boston, MA....
[2] BiondVax Pharmaceuticals Ltd.. (1/28/21). "Press Release: BiondVax Announces Third Quarter 2020 Financial Results & Business Update". Jerusalem....
[3] BiondVax Pharmaceuticals Ltd.. (1/21/21). "Press Release: BiondVax Announces Appointment of Amir Reichman as New CEO". Jerusalem....
[4] BiondVax Pharmaceuticals Ltd.. (10/23/20). "Press Release: BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate". Jerusalem....
[5] Blue Water Vaccinces, Inc.. (7/9/19). "Press Release: Blue Water Vaccines, Developing Universal Flu Vaccine, Completes $7m Financing Following Successful Preclinical Study". Cincinnati, OH & Oxford....
[6] ProBioGen AG. (5/15/19). "Press Release: ProBioGen and Vaccitech Sign License Agreement for ProBioGen’s Technology Platform". Berlin & Oxford....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]